Kolexia
Wuilleme Soraya Pharmacien
Wuilleme Soraya
Pharmacien
Hôpital Hôtel-Dieu Nantes
Nantes, France
75 Activités
1 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Myélome multiple Tumeurs à plasmocytes Maladie résiduelle Leucémies Lymphomes Leucémie aigüe myéloïde Tumeurs hématologiques Lymphome à cellules du manteau Leucémie myéloïde

Collaborateurs

Voir plus
Moreau Philippe
Moreau Philippe
Hôpital Hôtel-Dieu Nantes, Nantes, France
Bene Marie-Christine
Bene Marie-Christine
Hôpital Hôtel-Dieu Nantes, Nantes, France
Eveillard Marion
Eveillard Marion
Hôpital Hôtel-Dieu Nantes, Nantes, France
Debord Camille
Debord Camille
Hôpital Hôtel-Dieu Nantes, Nantes, France

Industries

Voir plus
Janssen
3 collaboration(s)
Dernière en 2022
Sanofi
1 collaboration(s)
Dernière en 2023
Amgen
1 collaboration(s)
Dernière en 2022
Sysmex
1 collaboration(s)
Dernière en 2022

Dernières activités

Voir plus
Hepatosplenic T-cell lymphoma displays an original oyster-shell cytological pattern and a distinct genomic profile from that of gamma-delta T-cell large granular lymphocytic leukemia.
Haematologica   25 janvier 2024
Artificial Intelligence Using Multimodal Data for Myelodysplastic Syndrome Screening
Annual Meeting Abstracts 2022   15 novembre 2022
Perls' Stain Guidelines from the French-Speaking Cellular Hematology Group (GFHC).
Diagnostics (Basel, Switzerland)   12 juillet 2022
IFM2014-02: IFM 2014-02 Study: A Randomized Phase III Study of Bortezomib-Melphalan 200 Conditioning Regimen Versus Melphalan 200 for Frontline Transplant Eligible Patients With Multiple Myeloma
Essai Clinique (Janssen)   17 mai 2022
Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study.
Blood   09 mai 2022
Molecular Signature of F-FDG PET Biomarkers in Newly Diagnosed Multiple Myeloma Patients: A Genome-Wide Transcriptome Analysis from the CASSIOPET Study.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine   27 janvier 2022
Daratumumab (DARA) with Bortezomib, Thalidomide, and Dexamethasone (VTd) in Transplant-Eligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) Negativity in Cassiopeia Part 1 and Part 2
Blood   23 novembre 2021
Peripheral Levels of Monocytic Myeloid-Derived Suppressive Cells at Diagnosis Predict Survivals in AML Patients Eligible for Intensive Chemotherapy
Blood   23 novembre 2021
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.
The Lancet. Oncology   13 septembre 2021
Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results.
Blood   30 juillet 2021